Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 3, 2005, Pages 608-615

  Burger, Marilise E ^a   Fachinetto, Roselei ^a   Zeni, Gilson ^a   Rocha, João B T ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Ebselen; Haloperidol; Orofacial dyskinesia; Tardive dyskinesia; TBARS

Indexed keywords

ANTIOXIDANT; EBSELEN; GLUTATHIONE PEROXIDASE; HALOPERIDOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BIOCHEMISTRY; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; INHIBITION KINETICS; MALE; MASTICATION; MUSCLE TWITCH; NONHUMAN; OBSERVATION; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; SYMPTOM; TONGUE;

ANIMALIA;

EID: 84984588461     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.05.002     Document Type: Article

References (75)

1. V.C. Abilio, J.A.R. Vera, L.S.M. Ferreira, C.R.M. Duarte, R.C. Carvalho, and C.C. Grassl Effects of melatonin on orofacial movements in rats Psychopharmacology 161 2002 340 347
2. V.C. Abilio, C.C.S. Araujo, M. Bergamo, P. Calvente, V. D'Almeida, and R.A. Ribeiro Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats Prog Neuropsychopharmacol Biol Psychiatry 27 2003 109 114
3. V.C. Abilio, C.C. Araujo, M. Bergamo, P.R. Calvente, V. D'Almeida, and R.de A. Ribeiro Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats Prog Neuropsychopharmacol Biol Psychiatry 27 1 2003 109 114
4. V.C. Abílio, R.H. Silva, R.C. Carvalho, C. Grassl, M.B. Calzavara, and S. Registro Important role of striatal catalase in aging-and reserpine-induced oral dyskinesia Neuropharmacology 47 2004 263 272
5. O.A. Andreassen, and H.A. Jorgensen GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats Psychopharmacology 116 1994 517 522
6. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61 2000 525 541
7. O.A. Andreassen, R.J. Ferrante, T.O. Aamo, M.F. Beal, and H.A. Jorgensen Oral dyskinesias and histopathological alterations in substantia nigra long-term haloperidol treatment of old rats Neuroscience 122 2003 717 725
8. S.L. Arnaiz, M.F. Coronel, and A. Boveris Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment Nitric Oxide Biol Chem 3 1999 235 243
9. R.J. Baldessarini, and F.I. Tarazi Drugs and the treatment of psychiatric disorders J.G. Hardman L.E. Limbird A.G. Gilman The pharmacological basis of therapeutics 2001 Goodman and Gilman's New York 485 520
10. Y. Barak, M. Swartz, E. Shamir, D. Stein, and A. Weizman Vitamin E (alpha-tocoferol) in the treatment of tardive dyskinesia: a statistical meta-analysis Ann Clin Psychiatry 10 1998 101 105
11. M. Bergamo, V.C. Abílio, C.M.T. Queiroz, H.N. Barbosa- Júnior, L.R.A. Abdanur, and R. Frussa-Filho Effects of age on a new model of tardive dyskinesia Neurobiol Aging 18 1997 623 629
12. M.B.E. Burger, A. Alves, L. Callegari, F.R. Athayde, C.W. Nogueira, and G. Zeni Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum Prog Neuropsychopharmacol Biol Psychiatry 27 2003 135 140
13. M. Burger, R. Fachinetto, L. Calegari, M.W. Paixao, A.L. Braga, and J.B.T. Rocha Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide Brain Res Bull 64 2004 339 345
14. M.B.E. Burger, R. Fachineto, A. Alves, L. Callegari, and J.B.T. Rocha Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats Brain Res 1031 2 2005 202 210
15. J.L. Cadet, J.B. Lohr, and D.V. Jeste Free radicals and tardive dyskinesia Trends Neurosci 9 1986 107 108
16. P.R.V. Calvente, C.C.S. Araujo, M. Bergamo, V.C. Abilio, V. D'Almeida, and R.D.A. Ribeiro The mitochondrial toxin 3-nitropropionic acid aggravates reserpina-induced oral dyskinesia in rats Prog Neuropsychopharmacol Biol Psychiatry 26 2002 401 405
17. S.C.G. Campos, D.A.C. Moreira, T.D. Silva Nunes, and P. Colepicolo Oxidative stress in alcohol-induced rat parotid sialadenosis Arch Oral Biol 50 2005 661 668
18. D.E. Casey Tardive dyskinesia - pathophysiology F.E. Bloom D.J. Kupfer Pyschopharmacology: the fourth generation of progress 1995 Raven Press Ltd New York 1497 1502
19. J.T. Coyle, and P. Puttfarcken Oxidative stress glutamate and neurodegenerative disorders Science 262 1993 689 695
20. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts and clinicalpharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
21. L.M. Dabiri, D. Pasta, J.K. Darby, and D. Mosbacher Effectiveness of vitamin E for treatment of long-term tardive dyskinesia Am J Psychiatry 151 1994 925 926
22. D.A. Dawson, H. Masayasu, D.I. Graham, and I.M. Macrae The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat Neurosci Lett 185 1995 65 69
23. M.F. Egan, T.M. Hyde, G.W. Albers, A. Elkashef, R.C. Alexander, and A. Reeve Treatment of tardive dyskinesia with vitamin E Am J Psychiatry 149 1992 773 777
24. A.M. Elkashef, P.E. Rustin, N. Bacher, and D. Barret Vitamin E in the treatment of tardive dyskinesia Am J Psychiatry 147 1990 505 506
25. L. Engman Expedient synthesis of ebselen and related compounds J Org Chem 54 1989 2964 2966
26. J.W. Grimm, P.J. Kruzich, and E. See Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation Pharmacol Biochem Behav 60 1998 167 173
27. H. Imai, H. Masayasu, D. Dewar, D.I. Graham, and I.M. Macrae Ebselen protects both gray model of focal and white matter in a rodent cerebral ischemia Stroke 32 2001 2149 2156
28. V. Jackson-Lewis, S. Przedborski, V. Kostic, F. Suber, S. Fahn, and J.L. Cadet Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha-tocopherol in rat brain Brain Res Bull 26 1991 251 258
29. M. Kasapoglu, and T. Özben Alterations of antioxidant enzimes and oxidative stress markers in aging Exp Gerontol 36 2001 209 220
30. S.M. Kashif, R. Zaidi, and Naheed Banu Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain Clin Chim Acta 340 2004 229 233
31. H.L. Klawans, and R. Rubovits An experimental model of tardive dyskinesia J Neural Transm 33 1972 235 246
32. R. Kumaraguruparan, J. Kabalimoorthy, and S. Nagini Correlation of tissue lipid peroxidation and menopausal status in patients with adenocarcinoma of the breast Clin Biochem 38 2005 154 158
33. P. Llorca, I. Chereau, F. Bayle, and C. Lancon Tardive dyskinesias and antipsychotics: a review Eur Psychiatr 17 2002 129 138
34. J.B. Lohr Oxygen free radicals and neuropsychiatric illness Arch Gen Psychiatry 48 1991 1097 1106
35. J.B. Lohr, R. Kuczenski, H.S. Bracha, M. Moir, and D.V. Jeste Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia Biol Psychiatry 28 2003 535 539
36. J.B. Lohr, R. Kuczenski, and A.B. Niculescu Oxidative mechanisms and tardive dyskinesia CNS Drugs 17 1 2003 47 62
37. G. Marchese, M.A. Casu, F. Bartholini, S. Ruiu, P. Saba, and G.L. Gessa Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing Eur J Neurosci 15 2002 1187 1196
38. C.K. Meshul, O.A. Andreassen, C. Allen, and H.A. Jorgensen Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol Psychopharmacology (Berl) 125 1996 238 247
39. S. Moussaoui, M. Obinu, N. Daniel, M. Reibaud, V. Blanchard, and A. Imperato The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease Exp Neurol 166 2000 235 245
40. A. Müller, H. Gabriel, and H. Sies A novel biologically active seleno-organic compound IV. Protective glutathione-dependent effect of PZ 51 (Ebselen) against ADP-Fe induced lipid peroxidation in isolated hepatocytes Biochem Pharmacol 34 1985 1185 1189
41. P.S. Naidu, and S.K. Kulkarni Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide Behav Pharmacol 12 2001 209 216
42. P.S. Naidu, A. Singh, and S.K. Kulkarni Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia Neuropharmacology 44 2003 1100 1106
43. S. Namura, I. Nagata, S. Takami, H. Masayasu, and H. Kikuchi Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice Stroke 32 2001 1906 1911
44. C.W. Nogueira, G. Zeni, and J.B.T. Rocha Organoselenium and organotellurium compunds: Toxicology and pharmacology Chem Rev 104 2004 6255 6285
45. H. Ohkawa, H. Ohishi, and K. Yagi Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction Anal Biochem 95 2004 351 358
46. O. Öztürk, and S. Gümüslü Age-related changes of antioxidant enzime activities, glutathione status and lipid peroxidation in rat erythrocytes after heat stress Life Sci 75 2004 1551 1565
47. M. Parnham, and H. Sies Ebselen:prospective therapy for cerebral ischaemia Expert Opin Investig Drugs 9 2000 607 619
48. J.C. Perry, M.A.B.F. Vital, R. Frussa-Filho, S. Tufik, and J. Palermo-Neto Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats Eur Neuropsychopharmacol 14 2004 127 133
49. M. Polydoro, N. Schröder, M.N.M. Lima, F. Caldana, D.C. Laranja, and E. Bromberg Haloperidol- and clozapine-induced oxidative stress in the rat brain Pharmacol Biochem Behav 78 2004 751 756
50. L.O. Porciúncula, J.B.T. Rocha, C.R. Boeck, D. Vendite, and D.O. Souza Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons Neurosci Lett 299 2001 217 220
51. V. Raghavendra, P.S. Naidu, and S.K. Kulkarni Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors Brain Res 904 2001 149 152
52. B. Ramachandran, K. Ravi, V. Narayanan, M. Kandaswarry, and S. Subramanian Effect of macrocyclic binuclear oxovanadium complex on tissue defense system in streptozotocin-induced diabetic rats Clin Chim Acta 345 2004 141 150
53. R. Rodrigo, R. Castillo, R. Carrasco, P. Huerta, and M. Moreno Diminution of tissue lipid peroxidation in rats is related to the in vitro antioxidant capacity of wine Life Sci 76 2005 889 900
54. J.I. Rossato, L.A. Ketzer, F.B. Centurião, S.J.N. Silva, D.S. Lûdtke, and G. Zeni Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain Neurochem Res 27 2002 297 303
55. J.I. Rossato, G. Zeni, C.F. Mello, M.E. Rubin, and J.B.T. Rocha Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic-acid administration in the rat Neurosci Lett 318 2002 137 140
56. E. Sahin, and S. Gümüslü Alterations in brain antioxidant status, protein oxidation and lipid peroxidation in response to different stress models Behav Brain Res 155 2004 241 248
57. I. Saito, T. Asano, K. Sano, K. Takakura, H. Aba, and T. Yoshimoto Neuroprotective effect of an antioxidant, Ebselen, in patients with delayed neurological deficits after aneurismal subarachnoid hemorrage Neurosurgery 42 1998 269 277
58. P. Seeman, T. Lee, M. Chaw-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717 719
59. E. Shamir, Y. Barak, I. Shalman, M. Laudon, N. Zisapel, and R. Tarrasch Melatonin treatment for tardive dyskinesia-a double-blind, placebo-controlled, crossover study Arch Gen Psychiatry 58 2001 1049 1052
60. B.R. Shivakumar, and V. Ravindranath Oxidative stress and thiol modification induced by chronic administration of haloperidol J Pharmacol Exp Ther 265 1993 1137 1141
61. H. Sies Ebselen, a selenoorganic compound as glutathione peroxidase mimic Free Radic Biol Med 14 1993 313 323
62. A. Singh, P.S. Naidu, and S.K. Kulkarni Possible antioxidant and neuroprotective mechanism of FK506 in attenuating haloperidol-induced orofacial dyskinesia Eur J Pharm 477 2003 87 94
63. D. Singh, V. Chander, and K. Chopra The effect of quercetin, a bioflavonoid on ischemia/reperfusion induced renal injury in rats Arch Med Res 35 2004 484 494
64. T. Takasago, E.E. Peters, D.I. Graham, H. Masayasu, and I.M. Macrae Neuroprotective efficacy of ebselen an antioxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion Br J Pharmacol 122 1997 1251 1256
65. H. Takeuchi, J. Ishigooka, K. Kobayashi, S. Watanabe, and S. Miura Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs Prog Neuropsychopharmacol Biol Psychiatry 22 1998 679 691
66. T. Tamaguchi, K. Sano, K. Takakura, I. Saito, Y. Shinohara, and T. Asano Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial Stroke 29 1998 12 17
67. G.C. Tsai, D.C. Golf, R.W. Chang, J. Flood, L. Baer, and J.T. Coyle Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am J Psych 155 1998 1207 1213
68. M.A.B.F. Vital, R. Frussa-Filho, and J. Palermo-Neto Effects of monosialoganglioside on a new model of tardive dyskinesia Prog Neuropsychopharmacol Biol Psychiatry 21 1997 1169 1179
69. M.A.B.F. Vital, J.C. Flório, Frussa-Filho, R. De Lucia, S. Tufik, and J. Palermo-Neto Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover Life Sci 62 1998 1161 1169
70. J.L. Waddington Spontaneous orofacial movements induced by very long-term neuroleptic drug administration: phenonomenology, pathophysiology and putative relationship to tardive dyskinesia Psychopharmacology 101 1990 431 447
71. A. Wendel, M. Fausel, H. Safayi, and R. Otter A novel biologically active seleno-organic compoud-II. Activity of PZ 51 in relation to glutathione peroxidase Biochem Pharmacol 33 1984 3241 3245
72. S. Wolfarth, and K. Ossowska Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog Neuropsychopharmacol Biol Psychiatry 13 1989 789 840
73. R. Zhao, and A.A. Holmgren A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase J Biol Chem 277 2002 39456 39462
74. T. Yamaguchi, K. Sano, K. Takakura, I. Saito, Y. Shinohara, and T. Asano Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial Stroke 29 1998 12 17
75. H. Yokoyama, N. Kasai, Y. Ueda, R. Niwa, R. Konaka, and N. Mori In vivo analyses of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic Free Radic Biol Med 24 1998 1056 1060